Cosibelimab
- Generic Name
- Cosibelimab
- Drug Type
- Biotech
- CAS Number
- 2216751-26-5
- Unique Ingredient Identifier
- PNW7GBB44P
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1
Not yet recruiting
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Arsen Osipov
- Target Recruit Count
- 24
- Registration Number
- NCT06981806
- Locations
- 🇺🇸
Cedars-Sinai Cancer at SOCC, Los Angeles, California, United States
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
Phase 3
Terminated
- Conditions
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Interventions
- Dietary Supplement: Folic acid 350-1000 μgDietary Supplement: Vitamin B12 1000 μg
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Checkpoint Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04786964
- Locations
- 🇹ðŸ‡
Research Site, Chiang Mai, Thailand
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Phase 1
Terminated
- Conditions
- B-cell Non Hodgkin LymphomaRichter's Transformation
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03778073
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath